Legalization of Psychedelics for Medical Use

The article discusses the push to legalize psychedelics, particularly MDMA, for medical use in treating PTSD. Despite promising results in studies, the FDA rejected the proposal from MAPS's pharmaceutical arm, leading to setbacks in the psychedelic movement. The rejection was influenced by concerns over the safety and efficacy of MDMA, including issues with research methodology and allegations of sexual misconduct. Critics argue that the psychedelic culture prioritizes recreational use over medical benefits, leading to a lack of rigorous clinical trials and protocols.